| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778656 | European Urology | 2017 | 8 Pages |
Abstract
Not all patients with prostate-specific antigen persistence have a poor prognosis. Pathologic characteristics should be used to estimate the risk of cancer-specific mortality in these individuals and to identify patients who could benefit from postoperative radiotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, Emanuele Zaffuto, Nicola Fossati, Marco Bandini, Paolo Dell'Oglio, Nazareno Suardi, Francesco Montorsi, R. Jeffrey Karnes, Alberto Briganti,